Brendan Teehan - 05 Apr 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP, COO, Head of Commercial
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 05 Apr 2023
Net transactions value: -$31,798
Form type: 4
Filing time: 07 Apr 2023, 20:44:46 UTC
Previous filing: 27 Feb 2023
Next filing: 02 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+5,024	+97%		10,219	05 Apr 2023	Direct	F1
transaction	ACAD	Common Stock	Sale	$31,798	-1,751	-17%	$18.16	8,468	06 Apr 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-5,024	-25%	$0.000000	15,072	05 Apr 2023	Common Stock	5,024		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3	The restricted stock units vest in four equal annual installments beginning April 5, 2023.